{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:42:00Z","timestamp":1793947320579,"version":"4.8.0"},"reference-count":17,"publisher":"Pensoft Publishers","issue":"3","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FM"],"abstract":"<jats:p>\n            <jats:bold>Abstract<\/jats:bold>\n          <\/jats:p>\n          <jats:p><jats:bold>Introduction:<\/jats:bold> Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous disorder with unknown etiology. Numerous treatment options have been reported, with topical corticosteroids being very often used as the first-line therapy for gingival lesions. However, a relatively novel therapeutic option is provided by tacrolimus.<\/jats:p>\n          <jats:p><jats:bold>Aim:<\/jats:bold> To compare the clinical effectiveness of topical tacrolimus 0.1% and clobetasol propionate 0.05% in the management of desquamative gingivitis, a distinct clinical manifestation of OLP.<\/jats:p>\n          <jats:p><jats:bold>Materials and methods:<\/jats:bold> This comparative study included 20 patients with histologically proven symptomatic OLP with gingival manifestation. The participants were divided into 2 groups: group A (clobetasol propionate 0.05% cream) and group B (topical tacrolimus 0.1% ointment). They were instructed to apply topical medications twice daily for three consecutive weeks. Custom trays have been used for better drug delivery. The patients were recalled at 1, 2, and 3 months after cessation of therapy for a follow-up control of any relapse.<\/jats:p>\n          <jats:p><jats:bold>Results:<\/jats:bold> The subjects in both groups showed a significant reduction in the burning sensation\/pain and discomfort according to the visual analog scale (VAS). Similarly, both groups showed reduction in the efficiency index, and moderate improvement especially was seen in the tacrolimus 0.1% group (53%) and the clobetasol propionate group 0.05% (47%). Patients treated with clobetasol propionate 0.05% didn\u2019t have a relapse at 2 and 3 months after cessation of treatment. In contrast, 30% of the patients treated with tacrolimus 0.1% had a relapse of the condition at 2 and 3 months.<\/jats:p>\n          <jats:p><jats:bold>Conclusions:<\/jats:bold> Tacrolimus can be considered as a good alternative topical medication in the treatment of OLP, especially in those patients that do not respond to topical corticosteroids.<\/jats:p>","DOI":"10.3897\/folmed.64.e62851","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T21:24:15Z","timestamp":1656537855000},"page":"415-421","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of clinical efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in desquamative gingivitis, manifestation of oral lichen planus"],"prefix":"10.3897","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-5361","authenticated-orcid":true,"given":"Lilia","family":"Kavlakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2258","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"62851_B1","doi-asserted-by":"crossref","unstructured":"1. Ismail SB, Kumar SKS, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci 2007; 49(2):89\u2013106.","DOI":"10.2334\/josnusd.49.89"},{"key":"62851_B2","doi-asserted-by":"crossref","unstructured":"2. Eisen D, Carrozzo M, Sebastian JVB, et al. Oral lichen planus: Clinical features and management. Oral Dis 2005; 11:338\u201349.","DOI":"10.1111\/j.1601-0825.2005.01142.x"},{"key":"62851_B3","doi-asserted-by":"crossref","unstructured":"3. Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:164\u201378.","DOI":"10.1016\/j.tripleo.2004.06.076"},{"key":"62851_B4","doi-asserted-by":"crossref","unstructured":"4. Cribier B, Frances C, Chosidow O. Treatment of lichen planus: an evidence-based medicine analysis of efficacy. Arch Dermatol 1998; 134:1521\u201330.","DOI":"10.1001\/archderm.134.12.1521"},{"key":"62851_B5","doi-asserted-by":"crossref","unstructured":"5. Carrozzo M, Gandolfo S. The management of oral lichen planus. Oral Dis 1999; 5(3):196\u2013205.","DOI":"10.1111\/j.1601-0825.1999.tb00301.x"},{"key":"62851_B6","doi-asserted-by":"crossref","unstructured":"6. Thongprasom K, Luangjarmekorn L, Sererat T, et al. Relative efficacy of flucinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med 1992; 21:456\u20138.","DOI":"10.1111\/j.1600-0714.1992.tb00974.x"},{"key":"62851_B7","doi-asserted-by":"crossref","unstructured":"7. Laeijendecker R, Tank B, Dekker SK, et al. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol 2006; 86(3):227\u201329.","DOI":"10.2340\/00015555-0070"},{"key":"62851_B8","unstructured":"8. Mutafchieva M. [Immunobiological effects of low-level laser therapy (LLLT) in the treatment of oral lichen planus. Experimental, laboratory and clinical studies.] [PhD thesis]. Plovdiv: Medical University of Plovdiv; 2018 [Bulgarian]."},{"key":"62851_B9","unstructured":"9. Lener E, Brieva J, Schacter M, et al. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 2001; 137:419\u201322."},{"key":"62851_B10","doi-asserted-by":"crossref","unstructured":"10. Rozycki TW, Rogers III RS, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002; 46:27\u201334.","DOI":"10.1067\/mjd.2002.119648"},{"key":"62851_B11","doi-asserted-by":"crossref","unstructured":"11. Aufdemorte TB, De Villez RL, Parel SM. Modified topical corticosteroid therapy for the treatment of oral mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol 1985; 59:256\u201360.","DOI":"10.1016\/0030-4220(85)90162-8"},{"key":"62851_B12","doi-asserted-by":"crossref","unstructured":"12. Thongprasom K, Luangjarmekorn L, Sererat T, et al. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med 1992; 21:456\u20138.","DOI":"10.1111\/j.1600-0714.1992.tb00974.x"},{"key":"62851_B13","doi-asserted-by":"crossref","unstructured":"13. Revanappa MM, Naikmasur VG, Sattur AP. Evaluation of efficacy of tacrolimus 0.1% in Orabase and triamcinolone acetonide 0.1% in Orabase in the management of symptomatic oral lichen planus. Randomized single blind control study. J Indian Acad Oral Med Radiol 2012; 24(4):269\u201373.","DOI":"10.5005\/jp-journals-10011-1311"},{"key":"62851_B14","doi-asserted-by":"crossref","unstructured":"14. Byrd JA, Davis MDP, Bruce AJ, et al. Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol 2004; 140:1508\u201312.","DOI":"10.1001\/archderm.140.12.1508"},{"key":"62851_B15","doi-asserted-by":"crossref","unstructured":"15. Radfar L, Wild RC, Suresh L. A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105:187\u201393.","DOI":"10.1016\/j.tripleo.2007.07.029"},{"key":"62851_B16","doi-asserted-by":"crossref","unstructured":"16. Lodi G, Giuliani M, Majorana A, et al. Lichen planus and hepatitis C virus: A multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 2004; 151:1172\u201381.","DOI":"10.1111\/j.1365-2133.2004.06257.x"},{"key":"62851_B17","unstructured":"17. Hodgson TA, Sahni N, Kaliakatsu F, et al. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative\/erosive lichen planus. Eur J Dermatol 2003; 13:466\u201370."}],"container-title":["Folia Medica"],"original-title":[],"link":[{"URL":"https:\/\/foliamedica.bg\/article\/62851\/download\/pdf\/","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article\/62851\/download\/xml\/","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article_preview.php?id=62851&skip_redirect=1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T21:24:25Z","timestamp":1656537865000},"score":1,"resource":{"primary":{"URL":"https:\/\/foliamedica.bg\/article\/62851\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,30]]}},"URL":"https:\/\/doi.org\/10.3897\/folmed.64.e62851","relation":{},"ISSN":["1314-2143","0204-8043"],"issn-type":[{"value":"1314-2143","type":"electronic"},{"value":"0204-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}